Research
Hormonal
Tirzepatide treatment led to increased HDL cholesterol levels and decreased LDL cholesterol and triglyceride levels.
Tirzepatide may improve overall lipid profiles in patients.
StrongSupportsmedium confidence
tirzepatide treatment led to increased high-density lipoprotein (HDL) cholesterol levels and decreased low-density lipoprotein (LDL) cholesterol and triglyceride levels.
Why this rating
Based on the meta-analysis of randomized controlled trials.
Source
Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials
Mehmet Kanbay et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15272
Meta-analysisCited 47×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 mmHg for 5 mg, -5.34 mmHg for 10 mg, and -5.77 mmHg for 15 mg.Strong
- Tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% for 5 mg, -4.63% for 10 mg, and -5.93% for 15 mg.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →